Lymphoma Clinical Trials
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Lymphoma
| Protocol | COG AHOD2131 |
|---|---|
| Cancer Type: | Classic Hodgkin Lymphoma |
| Fast Facts |
COG-AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Patients must be 5 to 60 years of age at the time of enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | COG ANHL1931 |
|---|---|
| Cancer Type: | Lymphoma |
| Fast Facts |
COG ANHL1931
A Randomized Phase 3 trial of Nivolumab (NSC#748726 IND#125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
This is an AYA protocol ≥ 2 years
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.
